journal article·2023-12Open access

A Pro‐Metastatic Derivatives Eliminator for In Vivo Dual‐Removal of Circulating Tumor Cells and Tumor‐Derived Exosomes Impedes their Biodistribution into Distant Organs

Ying Sun, Lei Xing, Jun Luo, Ming‐Tao Yu, Xiao‐Jie Wang, Yi Wang, Tian‐Jiao Zhou, Hu‐Lin Jiang

Advanced Science· Volume 10· Issue 34

Abstract

Abstract Circulating tumor cells (CTCs) and tumor‐derived exosomes (TDEs) play an irreplaceable role in the metastatic cascade and preventing them from reaching distant organs via blood circulation helps to reduce the probability of cancer recurrence and metastasis. However, technologies that can simultaneously prevent CTCs and TDEs from reaching distant organs have not been thoroughly developed until now. Here, inspired by hemoperfusion, a pro‐metastatic derivative eliminator (PMDE) is developed for the removal of both CTCs and TDEs from the peripheral blood, which also inhibits their biodistribution in distant organs. This device is designed with a dual antibody‐modified immunosorbent filled into a capture column that draws peripheral blood out of the body to flow through the column to specifically capture CTCs and TDEs, followed by retransfusing the purified blood into the body. The PMDE can efficiently remove CTCs and TDEs from the peripheral blood and has excellent biocompatibility. Interestingly, the PMDE device can significantly inhibit the biodistribution of CTCs and TDEs in the lung and liver by scavenging them. This work provides a new perspective on anti‐metastatic therapy and has broad prospects in clinical applications to prevent metastasis and recurrence.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Lattice Boltzmann Simulation Studies · Cancer Cells and Metastasis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals China Pharmaceutical University Nanjing 210009 China

Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases China Pharmaceutical University Nanjing 210009 China

Funding

National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions · Ministry of Education of the People's Republic of China · China Postdoctoral Science Foundation

References (45)

Show source-provided references
1. 10.1126/science.120354310.1126/science.1203543 ↗
2. 10.3322/caac.2166010.3322/caac.21660 ↗
3. 10.1016/j.apsb.2020.11.02410.1016/j.apsb.2020.11.024 ↗
4. 10.1038/nature1703810.1038/nature17038 ↗
5. 10.1158/2159-8290.CD-18-128510.1158/2159-8290.CD-18-1285 ↗
6. 10.1126/science.122852210.1126/science.1228522 ↗
7. 10.1021/acsnano.1c0980710.1021/acsnano.1c09807 ↗
8. 10.1038/s43018-021-00272-y10.1038/s43018-021-00272-y ↗
9. 10.1038/nature1575610.1038/nature15756 ↗
10. 10.1016/j.cmet.2021.09.00210.1016/j.cmet.2021.09.002 ↗
11. 10.1002/jev2.1216810.1002/jev2.12168 ↗
12. 10.1038/s41467-022-28438-x10.1038/s41467-022-28438-x ↗
13. 10.1016/j.ccell.2016.09.01110.1016/j.ccell.2016.09.011 ↗
14. Hart I. R. · Cancer Res. · 1980 · 40 · 2281
15. 10.1007/s10911-007-9047-310.1007/s10911-007-9047-3 ↗
16. 10.1038/nm.423910.1038/nm.4239 ↗
17. 10.1038/s41568-020-0246-110.1038/s41568-020-0246-1 ↗
18. Qiao F. · Int J Oncol · 2019 · 54 · 1525
19. 10.1038/s41551-018-0257-310.1038/s41551-018-0257-3 ↗
20. 10.1021/acs.analchem.0c0020310.1021/acs.analchem.0c00203 ↗
21. 10.1002/advs.20200094010.1002/advs.202000940 ↗
22. 10.1002/adma.20220787010.1002/adma.202207870 ↗
23. 10.1002/adfm.20180896110.1002/adfm.201808961 ↗
24. 10.1021/acs.nanolett.0c0095010.1021/acs.nanolett.0c00950 ↗
25. 10.1016/j.bios.2023.11529210.1016/j.bios.2023.115292 ↗
26. 10.1016/j.cell.2017.01.02610.1016/j.cell.2017.01.026 ↗
27. 10.1021/ac501243a10.1021/ac501243a ↗
28. 10.1039/C6CS00803H10.1039/C6CS00803H ↗
29. 10.1172/JCI8113510.1172/JCI81135 ↗
30. 10.1002/jev2.1219510.1002/jev2.12195 ↗
31. 10.1002/smll.20200779610.1002/smll.202007796 ↗
32. 10.1016/j.bios.2021.11310210.1016/j.bios.2021.113102 ↗
33. 10.1002/advs.20200158110.1002/advs.202001581 ↗
34. 10.1186/s13054-022-04009-w10.1186/s13054-022-04009-w ↗
35. 10.1016/j.actbio.2020.02.02810.1016/j.actbio.2020.02.028 ↗
36. 10.18632/oncotarget.1070510.18632/oncotarget.10705 ↗
37. 10.1177/11782234100040000410.1177/117822341000400004 ↗
38. 10.1039/C8SC04197K10.1039/C8SC04197K ↗
39. 10.1016/j.bioactmat.2021.12.01710.1016/j.bioactmat.2021.12.017 ↗
40. 10.1021/acsami.9b0295910.1021/acsami.9b02959 ↗
41. 10.3390/cancers1201012710.3390/cancers12010127 ↗
42. 10.1039/C3LC50689D10.1039/C3LC50689D ↗
43. 10.1039/C9TB02147G10.1039/C9TB02147G ↗
44. 10.1016/j.bioactmat.2021.05.01710.1016/j.bioactmat.2021.05.017 ↗
45. 10.1016/j.ccell.2023.01.00110.1016/j.ccell.2023.01.001 ↗